148 results match your criteria mortality p 


Open Repair versus Endovascular Repair in The Treatment of Symptomatic Popliteal Artery Aneurysms.

Ann Vasc Surg 2022 Jul 20. Epub 2022 Jul 20.

Division of Vascular and Endovascular Surgery, Department of Surgery, University of California San Diego, La Jolla, CA. Electronic address:

Objective: Endovascular and open surgical modalities are currently used to treat popliteal artery aneurysms (PAA). However, there is limited data on the comparative durability of both repairs to guide physicians especially in the treatment of patients presenting symptomatic. We aimed to study the comparative effectiveness of endovascular PAA repair (EPAR) versus open PAA repair (OPAR). Read More

View Article and Full-Text PDF

Female sex portends increased risk of major amputation following surgical repair of symptomatic popliteal artery aneurysms.

J Vasc Surg 2022 May 25. Epub 2022 May 25.

Division of Vascular and Endovascular Surgery, Department of Surgery, University of California, San Diego, La Jolla, CA. Electronic address:

Objective: Popliteal artery aneurysms (PAAs) are rare in women, with only ∼5% of all PAAs occurring in women. The aim of the present study was to investigate whether sex disparities exist for patients treated with open PAA repair.

Methods: We reviewed all patients with PAAs who had undergone open PAA repair in the Vascular Quality Initiative from January 2010 to July 2021. Read More

View Article and Full-Text PDF

Comparison of popliteal artery aneurysm outcomes after open repair and endovascular repair: reducing post-operative type II endoleak and sac enlargement.

Ann Transl Med 2021 Nov;9(22):1688

Department of Vascular Surgery, West China Hospital, Sichuan University, Chengdu, China.

Background: This cohort study aimed to evaluate the short- and long-term outcomes of open repair (OR) and endovascular repair (ER) and identify the most suitable graft and approach for treating popliteal artery aneurysm (PAA) patients.

Methods: The data of PAA patients from January 2000 to August 2020 were retrospectively collected and analyzed. The primary endpoints were 30-day mortality, peri-operative complication morbidity, post-operative type II endoleak, and sac- enlargement. Read More

View Article and Full-Text PDF
November 2021

Lobectomy with pulmonary artery angioplasty for lung cancer using video-assisted thoracic surgery versus open thoracotomy: a retrospective propensity matched analysis.

Transl Lung Cancer Res 2021 Oct;10(10):3943-3956

Department of Thoracic Surgery, West China Hospital, Chengdu, China.

Background: Pulmonary artery angioplasty (PAA) is an important surgical procedure to complete radical resection with maximum preservation of functioning pulmonary tissues when the pulmonary artery is involved. In this study, we aimed to evaluate the short- and long-term outcomes of PAA using video-assisted thoracic surgery (VATS) versus open thoracotomy (OT) in lung cancer surgery.

Methods: We retrospectively reviewed 214 patients who underwent PAA between November 2005 and October 2016. Read More

View Article and Full-Text PDF
October 2021

Pulmonary artery dissection in long standing idiopathic pulmonary arterial hypertension: A case report.

Radiol Case Rep 2022 Jan 15;17(1):227-231. Epub 2021 Nov 15.

Department of Radiology, The Ohio State University, Wexner Medical Center, 395 W 12th Ave, Columbus, OH 43210, USA.

Pulmonary arterial dissection (PAD) is a rare and often lethal complication of chronic pulmonary arterial hypertension (PAH), which may occurs in patients with idiopathic pulmonary arterial hypertension (IPAH) and potentially in those with connective tissue disorders. While rare, sudden death often occurs secondary to acute cardiac tamponade, as the pulmonary artery dissects into the pericardium; this diagnosis is often made postmortem. Nevertheless, with the proliferation of multidetector computed tomography (MDCT) as a diagnostic test, patients may be identified very early after symptom onset, prompting rapid intervention with decreased morbidity and mortality. Read More

View Article and Full-Text PDF
January 2022

Poricoic acid A induces apoptosis and autophagy in ovarian cancer via modulating the mTOR/p70s6k signaling axis.

Braz J Med Biol Res 2021 18;54(12):e11183. Epub 2021 Oct 18.

Department of Pharmacy, The 305 Hospital of PLA, Beijing, China.

Due to the high mortality and rapid disease progression, ovarian cancer remains one of the most common malignancies threatening the health of women. The present study was conducted to explore the anticancer effects and the underlying mechanisms of poricoic acid A (PAA), the main components of Poria cocos, on ovarian cancer. We investigated the anticancer effects of different concentrations of PAA in the SKOV3 cell line. Read More

View Article and Full-Text PDF
October 2021

Management of Incidental Peripheral Pulmonary Arterial Aneurysm by Interventional Radiology.

Cureus 2021 Aug 20;13(8):e17337. Epub 2021 Aug 20.

Interventional Radiology, Ascension Providence/Michigan State University, Southfield, USA.

A peripheral pulmonary arterial aneurysm (PAA) is an abnormal dilatation of the distal pulmonary artery consisting of all three vessel wall layers (the intima, media, and adventitia). It is a rare, potentially life-threatening entity. There is no defined standard for an abnormal amount of dilation of the distal pulmonary vasculature, however, the most common criteria used is a diameter greater than 1. Read More

View Article and Full-Text PDF

Pulmonary vasculitis in Hughes-Stovin syndrome (HSS): a reference atlas and computed tomography pulmonary angiography guide-a report by the HSS International Study Group.

Clin Rheumatol 2021 Dec 17;40(12):4993-5008. Epub 2021 Sep 17.

Serviço de Reumatologia, Hospital das Clínicas, Faculdade de Medicina, Universidade Federal de Goiás, Goiânia, GO, Brazil.

Introduction: Hughes-Stovin syndrome (HSS) is a systemic vasculitis characterized by widespread venous/arterial thrombosis and pulmonary artery aneurysms (PAAs), which is associated with serious morbidity and mortality. All fatalities reported in HSS resulted from unpredictable fatal suffocating hemoptysis. Therefore, it is necessary to recognize pulmonary complications at an early stage of the disease. Read More

View Article and Full-Text PDF
December 2021

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival.

J Immunother Cancer 2021 08;9(8)

Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA

Background: Several therapeutic options are now available in the adjuvant melanoma setting, mandating an understanding of their benefit‒risk profiles in order to make informed treatment decisions. Herein we characterize adjuvant nivolumab select (immune-related) treatment-related adverse events (TRAEs) and evaluate possible associations between safety and recurrence-free survival (RFS) in the phase III CheckMate 238 trial.

Methods: Patients with resected stage IIIB-C or IV melanoma received nivolumab 3 mg/kg every 2 weeks (n=452) or ipilimumab 10 mg/kg every 3 weeks for four doses and then every 12 weeks (n=453) for up to 1 year or until disease recurrence, unacceptable toxicity, or consent withdrawal. Read More

View Article and Full-Text PDF

A case report of pericallosal aneurysm successfully treated with flow diverter stents.

Radiol Case Rep 2021 Sep 2;16(9):2447-2449. Epub 2021 Jul 2.

Department of Radiology, Ha Noi Medical University, Ha Noi, Viet Nam.

Pericallosal artery aneurysm (PAA) is a relatively uncommon type of intracranial aneurysm that tends to rupture more frequently and cause higher mortality rates than other types of cerebral aneurysms. Surgery to address PAA is difficult due to its deep-seated location, the size of the aneurysmal sac, and the limited surgical field. In recent years, with the development of percutaneous interventions, endovascular treatment has become the preferred, minimally invasive intervention method for the treatment of pericallosal aneurysms. Read More

View Article and Full-Text PDF
September 2021

Outcomes of popliteal artery aneurysms treated by ligation and in-situ saphenous vein bypass.

Int Angiol 2021 Oct 18;40(5):435-441. Epub 2021 Jun 18.

Unit of Vascular and Endovascular Surgery, Department of Surgery, San Giovanni di Dio Hospital, Florence, Italy.

Background: Modality of elective repair (open or endovascular) of popliteal artery aneurysms (PAAs) is still debated. About open repair no strict evidence exists about the best surgical technique. The aim of this study was to report a 20-year experience with ligation and in-situ saphenous vein bypass for the elective treatment of PAAs. Read More

View Article and Full-Text PDF
October 2021

Is the routine use of antipseudomonal antibiotics in acutely exacerbated COPD patients indicated: A retrospective analysis in 437 ICU patients.

J Crit Care 2021 10 24;65:49-55. Epub 2021 May 24.

Charité - Universitätsmedizin Berlin, Department of Nephrology and Medical Intensive Care Medicine, Berlin, Germany.

Purpose: Chronic obstructive pulmonary disease (COPD) is a risk factor for acquiring multiple drug resistant bacteria. The main objective of this analysis was to question a beneficial outcome in the routine use of antipseudomonal antibiotics in the empiric treatment of severe AECOPD in Intensive Care Unit patients.

Material And Methods: We report a retrospective, observational cohort study in adult patients with severe AECOPD admitted to ICU at a tertiary care university hospital. Read More

View Article and Full-Text PDF
October 2021

A systematic review and meta-analysis of treatment and natural history of popliteal artery aneurysms.

J Vasc Surg 2022 01 29;75(1S):121S-125S.e14. Epub 2021 May 29.

Evidence-based Practice Center, Mayo Clinic Rochester, Rochester, Minn. Electronic address:

Objective: To summarize the best available evidence comparing open vs endovascular popliteal artery aneurysm (PAA) repair. We also summarized the natural history of PAAs to support of the Society for Vascular Surgery guidelines.

Methods: We searched MEDLINE, EMBASE, Cochrane databases, and Scopus for studies of patients with PAAs treated with an open vs an endovascular approach. Read More

View Article and Full-Text PDF
January 2022

Adherence to instruction for use after endovascular repair of popliteal artery aneurysm.

Vascular 2022 Apr 19;30(2):276-284. Epub 2021 Apr 19.

Department of Clinical Sciences, Lund University, Malmö, Sweeden.

Objectives: Endovascular repair (ER) of popliteal artery aneurysm (PAA) is an alternative to open repair. However, there is no standardized protocol for when to opt for ER and the decision is therefore at the discretion of the clinician. This study aims to evaluate the adherence to the Instruction For Use (IFU) in patients undergoing ER for PAA and factors associated with stent graft patency at one year. Read More

View Article and Full-Text PDF

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

Lancet Oncol 2021 05 12;22(5):655-664. Epub 2021 Apr 12.

EORTC Headquarters, Brussels, Belgium.

Background: The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo (hazard ratio 0·57 [98·4% CI 0·43-0·74]; p<0·0001). This study reports the results from the health-related quality-of-life (HRQOL) exploratory endpoint.

Methods: This double-blind, randomised, controlled, phase 3 trial was done at 123 academic centres and community hospitals across 23 countries. Read More

View Article and Full-Text PDF

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

Lancet Oncol 2021 05 12;22(5):643-654. Epub 2021 Apr 12.

EORTC Headquarters, Brussels, Belgium.

Background: The European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. At 15-month median follow-up, pembrolizumab improved recurrence-free survival (hazard ratio [HR] 0·57 [98·4% CI 0·43-0·74], p<0·0001) compared with placebo, leading to its approval in the USA and Europe. This report provides the final results for the secondary efficacy endpoint, distant metastasis-free survival and an update of the recurrence-free survival results. Read More

View Article and Full-Text PDF

IL-6 modulation for COVID-19: the right patients at the right time?

J Immunother Cancer 2021 04;9(4)

Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center; Department of Pathology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

The ongoing pandemic caused by the novel coronavirus SARS-CoV-2 has disrupted the global economy and strained healthcare systems to their limits. After the virus first emerged in late 2019, the first intervention that demonstrated significant reductions in mortality for severe COVID-19 in large-scale trials was corticosteroids. Additional options that may reduce the burden on the healthcare system by reducing the number of patients requiring intensive care unit support are desperately needed, yet no therapy has conclusively established benefit in randomized studies for the management of moderate or mild cases of disease. Read More

View Article and Full-Text PDF

Comparison of Outcomes for Open Popliteal Artery Aneurysm Repair Using Vein and Prosthetic Conduits.

Ann Vasc Surg 2021 Aug 2;75:69-78. Epub 2021 Apr 2.

Division of Vascular and Endovascular Surgery, Department of Surgery, New York University Langone Medical Center, New York, NY. Electronic address:

Background: Autologous vein is considered the preferred conduit for lower extremity bypass. There is, however, limited literature regarding conduit choice for open popliteal artery aneurysm (PAA) repair. We sought to compare outcomes of PAA repair using vein versus prosthetic conduits. Read More

View Article and Full-Text PDF

[email protected] aptamer nanocages as a high-efficiency drug and gene delivery system for targeted lung cancer therapy.

J Nanobiotechnology 2021 Feb 24;19(1):54. Epub 2021 Feb 24.

Institute of Nano Biomedicine and Engineering, Key Laboratory for Thin Film and Microfabrication Technology of the Ministry of Education, Shanghai Engineering Research Center for Intelligent Diagnosis and Treatment Instrument, Department of Instrument Science & Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, People's Republic of China.

Background: Gene and chemical therapy has become one of the rising stars in the field of molecular medicine during the last two decades. However, there are still numerous challenges in the development of efficient, targeted, and safe delivery systems that can avoid siRNA degradation and reduce the toxicity and adverse effects of chemotherapy medicine.

Results: In this paper, a highly efficient AS1411 aptamer modified, dsDNA and MMP-2 cleavable peptide-fabricated gold nanocage vehicle, which could load doxorubicin hydrochloride (DOX) and siRNAs to achieve a combination of tumor responsive genetic therapy, chemotherapy, and photothermal treatment is presented. Read More

View Article and Full-Text PDF
February 2021

Coronavirus disease 2019 (COVID-19): survival analysis using deep learning and Cox regression model.

Pattern Anal Appl 2021 15;24(3):993-1005. Epub 2021 Feb 15.

Faculty of Engineering, Delta University for Science and Technology, Gamasa, Egypt.

Coronavirus (COVID-19) is one of the most serious problems that has caused stopping the wheel of life all over the world. It is widely spread to the extent that hospital places are not available for all patients. Therefore, most hospitals accept patients whose recovery rate is high. Read More

View Article and Full-Text PDF
February 2021

External stenting and disease progression in vein grafts 1 year after open surgical repair of popliteal artery aneurysm.

J Vasc Surg 2021 08 14;74(2):521-527. Epub 2021 Feb 14.

Department of Vascular and Endovascular Surgery, Cantonal Hospital Aarau, Aarau, Switzerland; Department of Vascular and Endovascular Surgery, University Hospital Basel, Basel, Switzerland. Electronic address:

Objective: Open surgical repair remains the gold standard treatment for popliteal artery aneurysms (PAA). The objective of this study was to evaluate the safety of external stenting and its medium-term effect on vein graft disease after open PAA repair.

Methods: Between December 2017 and September 2019, 12 consecutive patients with PAA underwent open surgical repair with externally stented saphenous vein grafts. Read More

View Article and Full-Text PDF

A critical analysis of 57 cases of Hughes-Stovin syndrome (HSS). A report by the HSS International Study Group (HSSISG).

Int J Cardiol 2021 05 30;331:221-229. Epub 2021 Jan 30.

Clinical Department of Medical, Surgical and Health Science, University of Trieste, Piazzale Europa, 1, 34127 Trieste, TS, Italy.

Background: Hughes-Stovin syndrome (HSS) is a systemic disease characterized by widespread vascular thrombosis and pulmonary vasculitis with serious morbidity and mortality. The HSS International Study Group is a multidisciplinary taskforce aiming to study HSS, in order to generate consensus recommendations regarding diagnosis and treatment.

Methods: We included 57 published cases of HSS (43 males) and collected data regarding: clinical presentation, associated complications, hemoptysis severity, laboratory and computed tomography pulmonary angiography (CTPA) findings, treatment modalities and cause of death. Read More

View Article and Full-Text PDF

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.

J Immunother Cancer 2021 01;9(1)

European Institute of Oncology, Milan, Italy.

Background: Patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer. The impact of immune checkpoint inhibition (ICI) on the severity of COVID-19 illness is unknown. The aim of this study was to investigate whether ICI confers an additional risk for severe COVID-19 in patients with cancer. Read More

View Article and Full-Text PDF
January 2021

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in -mutant melanoma.

J Immunother Cancer 2020 12;8(2)

Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy.

Background: In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib (triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and trametinib (doublet) without reaching statistical significance. Mature results on PFS, duration of response (DOR), and overall survival (OS) are reported.

Methods: The double-blind, phase 2 part of KEYNOTE-022 enrolled patients with previously untreated -mutated advanced melanoma from 22 sites in seven countries. Read More

View Article and Full-Text PDF
December 2020

Pulmonary Artery-Tracheal Fistula After Coil Implantation for Behcet's Disease.

Cureus 2020 Oct 19;12(10):e11036. Epub 2020 Oct 19.

Cardiothoracic Surgery, Sanford Medical Center, Fargo, USA.

Behcet's disease (BD) is a rare autoimmune disorder that results in diffuse full-thickness vasculitis. Pulmonary artery aneurysms (PAAs) and hemoptysis are known complications of this disease process, with high morbidity and mortality for affected patients. Although medical, endovascular, and surgical treatment strategies have all been described in the literature, there are little data to describe the long-term outcomes of these various treatment modalities and there continues to be a lack of clearly defined algorithms for the management of these patients. Read More

View Article and Full-Text PDF
October 2020

Evolving impact of long-term survival results on metastatic melanoma treatment.

J Immunother Cancer 2020 10;8(2)

Melanoma Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy

Melanoma treatment has been revolutionized over the past decade. Long-term results with immuno-oncology (I-O) agents and targeted therapies are providing evidence of durable survival for a substantial number of patients. These results have prompted consideration of how best to define long-term benefit and cure. Read More

View Article and Full-Text PDF
October 2020

Therapy results of pericallosal aneurysms: A retrospective unicenter study.

Clin Pract 2020 Sep 18;10(3):1257. Epub 2020 Sep 18.

Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.

This retrospective study aims to compare treatment results of ruptured and unruptured pericallosal artery aneurysms (PAAs) regarding patient outcome and aneurysm recurrence after endovascular treatment (EVT) and neurosurgical treatment (NT). A total of 67 patients with PAA were admitted to our hospital, 44 patients with subarachnoidal hemorrhage (SAH) due to a ruptured PAA and 23 patients with unruptured PAA. The radiographic features of PAA were collected from pre-treatment digital subtraction angiography. Read More

View Article and Full-Text PDF
September 2020

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.

J Immunother Cancer 2020 06;8(1)

Center for Immuno-Oncology, University Hospital of Siena, Instituto Toscano Tumori, Siena, Italy.

Background: We have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysis reports a 5-year update of OS and safety.

Methods: This randomized, multicenter, double-blind, phase III trial included patients with untreated or previously treated unresectable stage III or IV melanoma. Read More

View Article and Full-Text PDF

Outcome of Open and Endovascular Repair in Patients with Acute Limb Ischemia Due to Popliteal Artery Aneurysm.

Ann Vasc Surg 2020 Aug 1;67:376-387. Epub 2020 Apr 1.

Department of Clinical Sciences, Lund University, Malmö, Sweden; Vascular Center, Department of Cardiothoracic and Vascular Surgery, Skåne University Hospital, Malmö, Sweden.

Background: Popliteal artery aneurysm (PAA) carries a risk of sudden thromboembolism, resulting in acute limb ischemia (ALI). Since 2010, all 65 year-old-men in Region Skåne are invited for abdominal aortic aneurysm (AAA) screening, and subsequently for PAA if AAA is detected. The aims of the study were to explore if the ratio of PAAs treated electively compared with acute has changed since the implementation of the AAA screening program and to investigate the risk factors for major amputation, mortality, and combined major amputation/mortality after acute open repair (OR) or endovascular repair (ER) for PAA with ALI. Read More

View Article and Full-Text PDF

Aneurysm Rupture and Mortality During the Waiting Time for a Customised Fenestrated/Branched Stent Graft in Complex Endovascular Aortic Repair.

Eur J Vasc Endovasc Surg 2020 Jul 31;60(1):44-48. Epub 2020 Mar 31.

Department of Vascular and Endovascular Surgery, Paracelsus Medical University Nuremberg, General Hospital Nuremberg, Germany.

Objective: Treatment of complex aortic pathologies with customised fenestrated/branched stent grafts (F/BEVAR) is associated with a longer waiting time to the procedure. This study aimed to investigate the prevalence of aneurysm rupture and mortality during the waiting time for a fenestrated/branched stent graft in a single centre.

Methods: All patients with a pararenal (PAA), thoraco-abdominal (TAAA), or aortic arch aneurysm planned to be treated with a customised F/BEVAR between January 2010 and December 2018 were included. Read More

View Article and Full-Text PDF